223 related articles for article (PubMed ID: 23543798)
1. The emerging role of high-dose-rate (HDR) brachytherapy as monotherapy for prostate cancer.
Yoshioka Y; Yoshida K; Yamazaki H; Nonomura N; Ogawa K
J Radiat Res; 2013 Sep; 54(5):781-8. PubMed ID: 23543798
[TBL] [Abstract][Full Text] [Related]
2. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
3. Brachytherapy: current status and future strategies -- can high dose rate replace low dose rate and external beam radiotherapy?
Morton GC; Hoskin PJ
Clin Oncol (R Coll Radiol); 2013 Aug; 25(8):474-82. PubMed ID: 23727431
[TBL] [Abstract][Full Text] [Related]
4. Results of high dose rate afterloading brachytherapy boost to conventional external beam radiation therapy for initial and locally advanced prostate cancer.
Pellizzon AC; Nadalin W; Salvajoli JV; Fogaroli RC; Novaes PE; Maia MA; Ferrigno R
Radiother Oncol; 2003 Feb; 66(2):167-72. PubMed ID: 12648788
[TBL] [Abstract][Full Text] [Related]
5. Normal tissue dosimetric comparison between HDR prostate implant boost and conformal external beam radiotherapy boost: potential for dose escalation.
Hsu IC; Pickett B; Shinohara K; Krieg R; Roach M; Phillips T
Int J Radiat Oncol Biol Phys; 2000 Mar; 46(4):851-8. PubMed ID: 10705005
[TBL] [Abstract][Full Text] [Related]
6. Modelling second malignancy risks from low dose rate and high dose rate brachytherapy as monotherapy for localised prostate cancer.
Murray L; Mason J; Henry AM; Hoskin P; Siebert FA; Venselaar J; Bownes P;
Radiother Oncol; 2016 Aug; 120(2):293-9. PubMed ID: 27370205
[TBL] [Abstract][Full Text] [Related]
7. Rates of rectal toxicity in patients treated with high dose rate brachytherapy as monotherapy compared to dose-escalated external beam radiation therapy for localized prostate cancer.
Parzen JS; Ye H; Gustafson G; Yan D; Martinez A; Chen PY; Ghilezan M; Sebastian E; Limbacher A; Krauss DJ
Radiother Oncol; 2020 Jun; 147():123-129. PubMed ID: 32276193
[TBL] [Abstract][Full Text] [Related]
8. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
[TBL] [Abstract][Full Text] [Related]
9. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue.
Brenner DJ; Martinez AA; Edmundson GK; Mitchell C; Thames HD; Armour EP
Int J Radiat Oncol Biol Phys; 2002 Jan; 52(1):6-13. PubMed ID: 11777617
[TBL] [Abstract][Full Text] [Related]
10. High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer.
Martinez AA; Demanes J; Vargas C; Schour L; Ghilezan M; Gustafson GS
Am J Clin Oncol; 2010 Oct; 33(5):481-8. PubMed ID: 19952715
[TBL] [Abstract][Full Text] [Related]
11. The emerging role of high-dose-rate brachytherapy for prostate cancer.
Morton GC
Clin Oncol (R Coll Radiol); 2005 Jun; 17(4):219-27. PubMed ID: 15997914
[TBL] [Abstract][Full Text] [Related]
12. High-dose-rate brachytherapy monotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer.
Yamazaki H; Masui K; Suzuki G; Nakamura S; Yamada K; Okihara K; Shiraishi T; Yoshida K; Kotsuma T; Tanaka E; Otani K; Yoshioka Y; Ogawa K
Radiother Oncol; 2019 Mar; 132():162-170. PubMed ID: 30416045
[TBL] [Abstract][Full Text] [Related]
13. High dose rate brachytherapy for prostate cancer.
Hoskin P
Cancer Radiother; 2008 Nov; 12(6-7):512-4. PubMed ID: 18755623
[TBL] [Abstract][Full Text] [Related]
14. Dosimetric comparison between treatment plans of patients treated with low-dose-rate vs. high-dose-rate interstitial prostate brachytherapy as monotherapy: Initial findings of a randomized clinical trial.
Major T; Polgár C; Jorgo K; Stelczer G; Ágoston P
Brachytherapy; 2017; 16(3):608-615. PubMed ID: 28325472
[TBL] [Abstract][Full Text] [Related]
15. High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer.
Demanes DJ; Martinez AA; Ghilezan M; Hill DR; Schour L; Brandt D; Gustafson G
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1286-92. PubMed ID: 21310546
[TBL] [Abstract][Full Text] [Related]
16. LDR vs. HDR brachytherapy for localized prostate cancer: the view from radiobiological models.
King CR
Brachytherapy; 2002; 1(4):219-26. PubMed ID: 15062170
[TBL] [Abstract][Full Text] [Related]
17. The role of high-dose rate brachytherapy in locally advanced prostate cancer.
Vicini FA; Vargas C; Edmundson G; Kestin L; Martinez A
Semin Radiat Oncol; 2003 Apr; 13(2):98-108. PubMed ID: 12728439
[TBL] [Abstract][Full Text] [Related]
18. High dose rate brachytherapy in the treatment of prostate cancer.
Vicini F; Vargas C; Gustafson G; Edmundson G; Martinez A
World J Urol; 2003 Sep; 21(4):220-8. PubMed ID: 12905008
[TBL] [Abstract][Full Text] [Related]
19. Use of gold markers for setup in image-guided fractionated high-dose-rate brachytherapy as a monotherapy for prostate cancer.
Ghadjar P; Gwerder N; Madlung A; Behrensmeier F; Thalmann GN; Mini R; Aebersold DM
Strahlenther Onkol; 2009 Nov; 185(11):731-5. PubMed ID: 19899006
[TBL] [Abstract][Full Text] [Related]
20. High-dose-rate brachytherapy for prostate cancer: Rationale, current applications, and clinical outcome.
Strouthos I; Karagiannis E; Zamboglou N; Ferentinos K
Cancer Rep (Hoboken); 2022 Jan; 5(1):e1450. PubMed ID: 34164950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
